Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Carbapenem-resistant Enterobacterales (CREs) are recognized as an urgent public threat by the Centers for Disease Control and Prevention. This study assesses the activity of humanized serum concentrations for meropenem (2 g Q8h), meropenem-vaborbactam (4 g Q8h), and ceftazidime-avibactam (2.5 g Q8h) against carbapenemase-producing (CP) (AR-1046blaKPC-3) and non-CP (AR-8blaACT-15) Enterobacter cloacae isolates in a 120 h in vitro pharmacodynamic model. Additionally, we compared antimicrobial administration as a bolus or extended infusion for each isolate and treatment. For the CP strain, all treatments with meropenem-vaborbactam and ceftazidime-avibactam were bacteriostatic through 24 h. Extended-infusion meropenem-vaborbactam exhibited the most prolonged bacteriostatic activity and was significantly more effective than ceftazidime-avibactam at 120 h (0.92 log10 lower mean colony count compared to extended-infusion ceftazidime-avibactam, P < 0.001). For the non-CP strain, all simulated treatments demonstrated initial bactericidal activity through 24 h, except for ceftazidime-avibactam bolus administration. Meropenem and meropenem-vaborbactam, administered as bolus dosing, each maintained significantly greater bacterial colony count reductions compared to extended infusion through 120 h against non-CP CRE (P < 0.01). No significant differences were found between bolus and extended infusion for ceftazidime-avibactam (P = 0.08). Resistance development was observed following treatment with meropenem monotherapy (minimum inhibitory concentrations increasing to >32 µg/mL for the non-CP isolate with extended infusion and to >32 µg/mL for the CP isolate with bolus and extended-infusion treatments) and ceftazidime-avibactam (minimum inhibitory concentration increase from 2 to 16 μg/mL with bolus dosing against the CP isolate). Meropenem-vaborbactam exposure did not result in the emergence of antimicrobial resistance in any of the tested models.

Cite

CITATION STYLE

APA

Lavoie, T., Sierra, T., Daffinee, K., Pogue, J. M., Achour, B., & LaPlante, K. (2025). Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. Antimicrobial Agents and Chemotherapy, 69(12). https://doi.org/10.1128/aac.00906-25

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free